source
- Incyte to acquire Vega Therapeutics for up to $2 billion, securing late-stage von Willebrand disease drugIncyte announced it will purchase Vega Therapeutics, a unit of Star Therapeutics, for $1.25 billion in cash with the possibility of receiving up to $750 million more if future sales targets are met…
- J&J to acquire Firefly Bio for $1 billion, adding degrader-antibody conjugate technologyJ&J announced it will acquire biotech startup Firefly Bio in an all‑cash transaction valued at $1 billion. The deal gives J&J access to Firefly’s degrader‑antibody conjugate platform, which blends…